12:00 AM
Mar 09, 2015
 |  BC Week In Review  |  Clinical News  |  Regulatory

MammaPrint FFPE regulatory update

FDA granted 510(k) clearance to Agendia’s MammaPrint FFPE test to predict the risk of breast cancer recurrence...

Read the full 62 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >